Table 1 Demographics and clinical characteristics in all Chinese participants receiving study treatment
Demographic | Rimegepant 75 mg n = 538 | Placebo n = 537 | Overall N = 1075 |
|---|---|---|---|
Age, years | |||
Mean (SD) | 37.3 (10.2) | 36.7 (10.4) | 37.0 (10.3) |
Median (range) | 36 (19–71) | 35 (18–70) | 35 (18–71) |
Sex, n (%) | |||
Female | 412 (76.6) | 437 (81.4) | 849 (79.0) |
Male | 126 (23.4) | 100 (18.6) | 226 (21.0) |
Body mass indexa, kg/m2 | |||
Mean (SD) | 22.9 (3.4) | 23.1 (3.4) | 23.0 (3.4) |
Median (range) | 22.5 (15.6–47.0) | 22.8 (15.5–35.8) | 22.7 (15.5–47.0) |
Primary migraine type, n (%) | |||
Without aura | 476 (88.5) | 476 (88.6) | 952 (88.6) |
With aura | 62 (11.5) | 61 (11.4) | 123 (11.4) |
Age at disease onsetb, years | |||
Mean (SD) | 27.1 (9.2) | 26.2 (8.6) | 26.7 (8.9) |
Median (range) | 27 (3–49) | 26 (6–49) | 26 (3–49) |
Average duration of untreated attacks, hours | |||
Mean (SD) | 18.0 (14.7) | 18.4 (14.7) | 18.2 (14.6) |
Median (range) | 12 (4–72) | 12 (4–72) | 12 (4–72) |
Number of attacks with moderate or severe pain intensity per month | |||
Mean (SD) | 3.5 (1.3) | 3.4 (1.2) | 3.5 (1.2) |
Median (range) | 3 (2–8) | 3 (2–8) | 3 (2–8) |
Historically most bothersome symptom, n (%) | |||
Nausea | 281 (52.2) | 278 (51.8) | 559 (52.0) |
Phonophobia | 155 (28.8) | 157 (29.2) | 312 (29.0) |
Photophobia | 102 (19.0) | 101 (18.8) | 203 (18.9) |
Missing | 0 | 1 (0.2) | 1 (0.1) |
Took preventive migraine treatment previously, n (%) | 21 (3.9) | 17 (3.2) | 38 (3.5) |